Can Fite (Israel) Financial Diagnostics

CANF -- Israel Stock  

ILS 234.30  1.30  0.56%

Can Fite BioPharma Ltd diagnostics interface makes it easy to digest most current publicly released information about Can Fite as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis Can Fite price relationship with some important fundamental indicators such as market cap and management efficiency.

Can Fite Note

The company recorded loss per share of 0.15. Can Fite BioPharma Ltd had not issued any dividends in recent years. This company had a split on 2013-05-12. Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel. Can Fite is traded on Tel Aviv Stock Exchange in Israel. For more info on CAN-FITE BIOPHARMA please contact Pnina Fishman at 972 3 924 1114 or go to http://www.canfite.co.il.

Can Fite BioPharma Alerts

Can Fite BioPharma generates negative expected return over the last 30 days
The company reported revenue of 1.4 M. Net Loss for the year was (4.95 M) with profit before overhead, payroll, taxes, and interest of 2.94 M.
CAN-FITE BIOPHARMA has accumulated about 8.31 M in cash with (33.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.24.
Latest headline from cardinalweekly.com: It Seems Can-fite Biopharma Ltd Sponsored Adr Will Go Up. Just Reported Less ...

Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 88.4 M.

Management Efficiency

Can Fite BioPharma Ltd has return on total asset (ROA) of (34.8) % which means that it has lost $34.8 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (73.21) % meaning that it generated substantial loss on money invested by shareholders.

Technical Drivers

Can Fite BioPharma Ltd shows Risk Adjusted Performance of 0.01 and Mean Deviation of 1.21. Can Fite BioPharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm future prices. In plain English you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum or the prices will eventually revert. We found nineteen technical drivers for Can Fite BioPharma Ltd which can be compared to its rivals. Please confirm Can Fite BioPharma Standard Deviation, Information Ratio, Treynor Ratio, as well as the relationship between Variance and Jensen Alpha to decide if Can Fite BioPharma is priced correctly providing market reflects its regular price of 234.3 per share.

Can Fite BioPharma Price Movement Analysis

Study
Time Period
Deviations up
Deviations down
MA Type
  Portfolio Suggestion    
  
Execute Study
 
null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Can Fite middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Can Fite BioPharma. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target. View also all equity analysis or get more info about bollinger bands overlap studies indicator.

Can Fite Technical and Predictive Indicators

Can Fite Forecast Models

Did you try this?

Run Portfolio Diagnostics Now

   

Portfolio Diagnostics

Use generated alerts and portfolio events aggregator to diagnose current holdings
All  Next Launch Portfolio Diagnostics

Also Currentnly Active

Purchased over 90 shares of
2 days ago
Traded for 26.13
Purchased over 90 shares of
2 days ago
Traded for 80.82
Purchased over 90 shares of
2 days ago
Traded for 42.67
Check also Trending Equities. Please also try Price Transformation module to use price transformation models to analyze depth of different equity instruments across global markets.
Search macroaxis.com